Novo Nordisk
on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.
Early analysis from a phase 3 REDEFINE 1 trial showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% on average after 68 weeks, compared to 2.3% for those on placebo, the company said.
Cagrilintide is a nascent form of weight loss treatment which differs existing GLP-1s, such as Novo Nordisk″s Wegovy and Eli Lilly’s Zepbound. The long-acting amylin analogue which works by mimicking a hormone that is co-secreted with insulin in the pancreas to increase satiety.
The drug maker also pointed to the treatment’s increased tolerability profile, describing it as “well-tolerated” with the most common side effects being gastrointestinal and mainly “mild to moderate.”
